Skip Navigation LinksHome > April 13, 2001 - Volume 15 - Issue 6 > Sex differences in HAART-associated dyslipidaemia
AIDS:
Clinical Science

Sex differences in HAART-associated dyslipidaemia

Pernerstorfer-Schoen, Heidemarie; Jilma, Bernda; Perschler, Alina; Wichlas, Sibylle; Schindler, Karinb; Schindl, Andreasc; Rieger, Armin; Wagner, Oswald F.d; Quehenberger, Peterd

Free Access
Article Outline
Collapse Box

Author Information

From the From the Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, the aDepartment of Clinical Pharmacology, the bInstitute of Nutritional Sciences, the cDivision of Special and Environmental Dermatology and the dDepartment of Medical and Chemical Laboratory Diagnostics, University of Vienna Medical School, Vienna General Hospital, Vienna, Austria.

Received: 5 June 2000;

revised: 12 October 2000; accepted: 1 February 2001.

Requests for reprints to: P. Quehenberger, Department of Medical and Chemical Laboratory Diagnostics, University of Vienna Medical School, Waehringer Guertel 18–20, A-1090 Vienna, Austria.

Collapse Box

Abstract

Objectives: Because female sex protects against dyslipidaemia and atherosclerosis in normal subjects, we aimed to reveal potential sex differences in metabolic side-effects of a newly initiated highly active antiretroviral therapy (HAART) regimen, and to relate these changes to endothelial cell activation as measured by levels of circulating E-selectin (cE-selectin).

Design: Prospective longitudinal cohort study.

Setting: Tertiary care centre at a University Hospital.

Methods: HIV-seropositive male (n = 27) and female patients (n = 13) with a plasma viral load of ≥ 10 000 copies/ml and 35 healthy controls were enrolled in the study. All participants were weight stable, free of acute opportunistic infections, and had not taken any protease inhibitors before. Serum levels of lipids, insulin, leptin, and cE-selectin were measured before initiation of HAART, and at 3 and 6 months thereafter.

Results: HAART increased serum levels of triglycerides, leptin, and low-density lipoprotein (LDL) cholesterol; these effects were more distinct in women. Fasting insulin levels and the LDL : high density lipoprotein (HDL) ratio increased only in female HIV-infected patients (P < 0.02 versus men). In contrast, endothelial activation, as measured by cE-selectin, decreased more in men (P < 0.02) than in women. As a consequence, women had higher triglycerides and leptin levels after therapy than did men, and the LDL : HDL ratio and cE-selectin levels, which were initially higher in men, were no longer different between the sexes.

Conclusions: Metabolic adverse effects during HAART are more pronounced in women than in men. Hence, female HIV-infected patients seem to loose part of their natural protection from atherosclerosis during antiretroviral therapy.

Back to Top | Article Outline

Introduction

The HIV epidemic has entered a new phase in the industrialized countries. Human HIV infection has moved off the list of the 15 leading causes of death for the first time since 1987 [1] because an increasing number of effective antiretroviral agents has become available. The use of combinations of these drugs delays disease progression and extends life expectancy in HIV-infected individuals [2].

The current mainstay in HIV therapy usually consists of a combination of at least three drugs, and frequently includes a protease inhibitor (PI) in addition to two nucleoside analogue reverse transcriptase inhibitors (NRTI) [3]. However, a variety of metabolic disturbances have recently been reported to be associated with antiretroviral treatment [4–8]. Whether these changes occur as a result of therapy containing PI or other components, or whether these changes occur because effective treatment has allowed the patients to survive to the point in time at which this syndrome would develop naturally, has not yet been elucidated.

Amongst the reported side-effects of highly active antiretroviral therapy (HAART) regimens are increases in serum triglycerides, low-density lipoproteins (LDL), total cholesterol and insulin levels. These changes in lipid profiles have raised clinical concern with respect to the atherogenic risk.

It is well known that female sex exerts anti-atherogenic–cardioprotective effects which can be explained in part by the effect of oestrogens on lipoprotein subfractions [i.e. decreasing LDL levels and increasing high-density lipoprotein (HDL) levels] [9,10]. However, it is not known whether female sex provides any protection against the negative effects of PI on lipid metabolism. Furthermore, it is unclear whether antiretroviral therapy may affect variables of lipid metabolism differently in male and female patients. This is of interest because HIV infection in the industrialized countries is no longer a problem afflicting primarily men; because of heterosexual transmission the number and proportion of HIV-infected women has increased constantly throughout the past decade [11].

Data on sex-specific metabolic effects of long-term HIV therapy are scarce because most studies have had a cross-sectional design. To the best of our knowledge, no such longitudinal data are available to date. Most of the recent reports dealing with drug-associated adverse effects are limited to men [6,12], or address mixed populations [5,7,8,13], and only a few reports focus on metabolic disturbances in women treated for HIV infection [14].

We therefore studied prospectively the effects of a newly initiated HAART regimen firstly to reveal potential sex differences in changes of serum levels of lipids, insulin, and leptin and secondly to determine their relationship to endothelial cell (EC) activation as measured by circulating E-selectin (cE-selectin).

Back to Top | Article Outline

Materials and methods

Study design

Prospective longitudinal cohort study in clinically stable HIV-infected male and female patients and healthy controls at a tertiary care centre of a University Hospital. As it is currently considered inappropriate to withhold HAART from HIV-infected individuals at high risk of progression [3], we did not assign an additional placebo-controlled group of patients to single out the effects of a PI-containing HAART on metabolic disturbances.

Back to Top | Article Outline
Ethical approval

Patients and controls gave written informed consent after approval of the study protocol by the Ethics Committee of the Vienna University Hospital.

Back to Top | Article Outline
Study population

Forty clinically stable outpatients (27 men, 13 pre-menopausal women; mean age, 36 years; range, 22–51 years) with HIV infection documented by enzyme-linked immunosorbent assay and confirmatory immunoassay, were recruited from the HIV outpatient clinic of the Vienna University Hospital.

Body composition and resting energy expenditure data of a subset of the patients have been reported previously [15].

An additional group of 35 HIV-seronegative, healthy volunteers, who were matched for age, sex and body mass index, served as controls and underwent metabolic and adhesion molecule assessment in the same setting.

Back to Top | Article Outline
Inclusion criteria

After a screening examination and recording of the Centers for Disease Control and Prevention (CDC) status [16], patients were enrolled in the study if they had never been treated with any HIV-1 PI before. All patients had to fulfil the criteria for initiation or intensification of antiretroviral therapy according to the guidelines of the International AIDS Society [3]

The following exclusion criteria were defined to isolate direct or indirect effects of HAART on parameters of lipid and glucose metabolism and EC activation: opportunistic infection within 12 weeks of screening, persisting fever (> 37.8°C), night sweat and/or elevation of C-reactive protein (CRP > 1 mg/dl) 6 weeks prior to the beginning of the study [17]; malignancy; pre-existing endocrinological and/or cardiovascular disease [18]; and therapy with or intake of substances known to influence lipid or glucose metabolism.

Patients who developed opportunistic infections during the course of the study or who did not adhere to the study protocol were excluded from final evaluation.

A uniform triple combination therapy was administered to all patients according to the current guidelines for antiretroviral treatment [3] : (i) one PI [nelfinavir (Roche, Vienna, Austria), 750 mg three times per day]; and (ii) two NRTI, [didanosine (Bristol-Myers Squibb, Vienna, Austria) 400 mg four times per day (250 mg for body weight < 60 kg) and stavudine (Bristol-Myers Squibb, Vienna, Austria) 40 mg twice per day (30 mg for body weight < 60 kg)]. The choice of this triple regimen was based on practical issues such as regimen complexity, drug interactions and tolerance, to maximize therapeutic benefit over time, and finally, on financial aspects concerning the reimbursement for medication by health insurance companies. To rule out substance-specific effects [19] all patients were treated uniformly with the same antiretroviral regimen.

Back to Top | Article Outline
Experimental protocol

Patients were evaluated shortly before the initiation of HAART and at 12 and 24 weeks thereafter.

Venous blood samples were obtained by atraumatic venipuncture after an overnight fast to measure fasting serum triglycerides, total cholesterol, LDL, HDL, serum insulin, leptin, cE-selectin, peripheral blood CD4 lymphocyte subset count and plasma viral load. Urine and stool cultures were performed for analysis of urogenital and gastrointestinal pathogens.

The occurrence of side-effects, the patients’ clinical course, and their adherence to HAART were controlled every 4 weeks during interviews performed routinely at the outpatient clinic.

Back to Top | Article Outline
Body composition

Body composition was assessed as described previously [15] after an overnight fast, and after voiding, within the first 5 min of resting in the supine position. A bioimpedance apparatus operating at 50 kHz (Bioelectrical Impedance Analyzer Model BIA-101; RJL Systems, Florence, Italy) was used with standardized procedures [20,21]. Body composition parameters were evaluated using the software BODYGRAM2 Version 2.2 (Akern, Florence, Italy). Fat-free mass was calculated by Kotler's corrected sex-specific predictive equation for fat-free mass, using parallel impedance, height, and weight [22], and fat mass was calculated as follows: fat mass = kg body weight − free fat mass.

Back to Top | Article Outline
Laboratory assays

After venipuncture with a 21-gauge needle, blood was collected into Vacutainer tubes (Becton Dickinson; Meylan Cedex, France) and centrifuged at 2000 g for 15 min at 4°C, aspirated and stored at −80°C until analysis; all samples were assayed in duplicate.

Serum triglycerides (Triglyceride GPO-PAP Test; Roche Diagnostics, Vienna, Austria), serum cholesterol (Cholesterol CHOD-PAP Test; Roche Diagnostics, Vienna, Austria) and direct measurement of HDL-cholesterol (HDL-C Plus; Roche Diagnostics, Vienna, Austria) were performed on a Hitachi 747 analyser (Roche Diagnostics, Vienna, Austria). LDL cholesterol was calculated according to the Friedewald formula.

Concentrations of cE-selectin and of human leptin were determined by commercially available enzyme immune assay kits (R & D Systems, Biomedica, Vienna, Austria and R & D Systems, BioVendor, Brno, Czech Republic respectively) [23]. Serum insulin was measured by radioimmune assay (RIA) (Serono, Freiburg, Germany) [24].

Back to Top | Article Outline
Plasma HIV RNA quantification

Plasma HIV-RNA levels were determined using an in vitro nucleic acid amplification test, lower limit of detection: 50 copies/ml (Roche Ultrasensitive Assay®, Roche Diagnostics, Vienna, Austria).

Back to Top | Article Outline
CD4 cell counts

Peripheral blood CD4 lymphocyte subset counts were determined by FACScan flow cytometer using monoclonal antibodies, and the Cellquest software (Becton-Dickinson, Mountain View, California, USA) [25].

Back to Top | Article Outline
Data analysis

Data is expressed as mean and the range, unless stated otherwise. Statistical calculations were carried out by using the StatView 5.0 Power PC Version software package (SAS Institute, Cary, North Carolina, USA), using non-parametric methods because data was distributed non-normally. Comparisons between groups were carried out by using the Mann–Whitney U test. Changes within the treatment groups were tested using the Friedman ANOVA and the Wilcoxon signed ranks test for post hoc comparisons. Correlations between parameters within each group were calculated with the non-parametric Spearman test. A two-tailed P value of < 0.05 was considered significant.

Back to Top | Article Outline

Results

Forty HIV-seropositive patients were included in the study (27 men, 13 women). Recruitment of consecutive patients resulted in a male : female sex distribution of approximately 2 : 1, which reflects the current sex distribution of newly HIV-infected patients in industrialized countries.

Seventeen of the patients (43%) had AIDS as defined by the CDC classification [16] (eight men, nine women); no patient was suffering from HIV-associated wasting. Baseline levels of measured outcome parameters were not different between HIV-infected and AIDS patients (all P values > 0.05).

Demographics of patients and healthy controls are given in Table 1, and final outcome values for lipids, insulin, leptin, and cE-selectin are presented in Table 2.

Table 1
Table 1
Image Tools
Table 2
Table 2
Image Tools

Five participants (three men, two women) dropped out of the study before final evaluation. Reasons for exclusion were discontinuation of therapy (one patient), switch to different (reverse transcriptase inhibitor only) antiretroviral regimens (two patients), lost to follow-up (two patients).

One female patient developed subjective symptoms of incipient lipodystrophy after 5 months of therapy. As she decided to leave the study on her own will and to discontinue medication (see above) she was not evaluated further.

Back to Top | Article Outline
Lipids, insulin and leptin
Baseline

Baseline fasting serum triglycerides, levels of insulin, leptin, and LDL were similar in patients and controls (P values > 0.05 versus control). However, the LDL : HDL ratio was > 25% higher in HIV-infected patients than in matched controls (P < 0.02, Table 1), which was due mainly to the 25% lower serum HDL levels in HIV-positive patients.

Back to Top | Article Outline
Influence of sex

Levels of triglycerides, insulin, leptin, and LDL were similar in both sexes (P > 0.05 between groups). Yet, serum HDL was approximately 20% lower in men, and hence, the LDL : HDL ratio was more than 40% higher in male than in female patients (P < 0.02 between groups, Table 1).

Back to Top | Article Outline
Body weight and body composition
Baseline and influence of sex

Baseline body weight, total body fat mass, and body fat as a percentage of body weight were similar in patients and controls (P values > 0.05 versus control).

Despite the 20% weight difference between HIV-infected men and women (P < 0.02, Table 1), baseline fat mass was similar in both sexes (P > 0.05, Table 1).

Accordingly, percentage body fat for men averaged 17% and for women, 24% (Table 1). The fact that our female patients had almost 30% greater relative fat mass than our male patients corresponds to the usual sex difference in body composition.

Back to Top | Article Outline
Effects of antiretroviral therapy on lipids, insulin leptin and fat mass

HAART increased serum levels of triglycerides, leptin, LDL and HDL, in both sexes (P < 0.05, Table 2, Fig. 2). However, insulin and the LDL : HDL ratio increased significantly only in female patients (P < 0.02 in females), and trend-wise in male patients (Table 2, Fig. 1, Fig. 2).

Fig. 2
Fig. 2
Image Tools
Fig. 1
Fig. 1
Image Tools

After therapy, triglyceride and leptin levels were higher in female patients (P < 0.02 between sexes), and LDL and the LDL : HDL ratio were no longer different from those in men (P > 0.05 between sexes).

Percentage body fat was 30% higher in women than in men not only at baseline, but also at final evaluation, due to the similar gain in fat mass in both sexes during HAART (Fig. 2).

There was a moderate correlation between serum leptin levels and body fat mass in both HIV-infected men and women at baseline (r = 0.64 and r = 0.68, respectively, P < 0.02 for both sexes). Positive correlations between the gain in serum leptin levels and in fat mass were noted only in women during HAART (r = 0.63, P < 0.03).

In contrast, baseline serum insulin levels did not correlate with baseline fat mass (r = 0.34 in men, r = 0.24 in women, P > 0.05 for both sexes), and the increase in serum insulin did not correlate with the gain in fat mass during therapy (r = 0.35 in men, r = 0.25 in women, P > 0.05 for both sexes).

Back to Top | Article Outline
Endothelial activation
Baseline and influence of sex

Baseline levels of cE-selectin were > 50% higher in patients than in controls (P < 0.02), and they were approximately 50% higher in HIV-infected males than in HIV-infected females (P < 0.02 between groups, Table 1).

Back to Top | Article Outline
Effects of antiretroviral therapy

During antiretroviral treatment, cE-selectin decreased significantly in males (P < 0.02) and only trend-wise in females (Table 2). As a consequence, cE-selectin was no longer different between male and female patients after 6 months of HAART (P > 0.05 between sexes).

Back to Top | Article Outline
Viral load and CD4 lymphocytes
Baseline and influence of sex

Levels of plasma viral load and CD4 lymphocytes did not differ between sexes (P > 0.05).

Back to Top | Article Outline
Antiviral effectiveness is similar between sexes

As shown by Table 2, HIV RNA plasma levels decreased to < 200 copies/ml after 24 weeks of PI-containing HAART irrespective of sex (P > 0.05 between groups). Twenty-three out of 40 patients even reached the lower level of detectability, i.e. 50 copies/ml after 8 weeks (two patients), after 12 weeks (seven patients), and after 24 weeks (14 patients) of PI treatment. CD4 lymphocytes increased equally in both sexes during therapy (P > 0.05 between groups, Table 2).

Back to Top | Article Outline

Discussion

Dyslipidaemia and asymptomatic atherosclerotic lesions are more frequent in HIV-positive patients than in healthy controls [17,26,27]. The risk to these patients of developing cardiovascular complications may increase further during long-term use of antiviral therapy [28].

As female sex protects from cardiovascular disease in HIV-seronegative subjects, we set out to study prospectively sex-differences in metabolic side-effects of a newly initiated HAART regimen, in particular to evaluate whether female sex is protective in this setting.

Back to Top | Article Outline
Cholesterol

In good agreement with previous findings, HIV-infected patients had lower baseline levels of HDL than healthy age-matched controls [17] (Table 1), whereas levels of LDL (Table 1) and total cholesterol were not different from control values. The latter finding is possibly due to the relatively good immune and the adequate nutritional status of our HIV-patients, who were also free of opportunistic infections or wasting.

Hence, the baseline LDL : HDL ratio, an established indicator of cardiovascular risk, was higher in HIV-patients than in controls, and higher in HIV-infected men than HIV-infected women (Fig. 1). The less favourable lipid profiles in our male patients before the start of HAART mirror nicely what is seen in the general population, i.e. the well-known increased risk for cardiovascular disease in men as compared with women [9,29]. Thus, HIV-infected women seem to be naturally better ‘protected’ from the pro-atherogenic effects of HIV-infection per se than are men.

However, after initiation of a combined antiretroviral therapy, LDL : HDL ratios increased only in our female HIV patients (Fig. 1) due to increases in LDL (Table 2). As a consequence, the baseline sex difference in the LDL : HDL ratio finally disappeared (Fig. 1). Hence, women seemed to have ‘lost’ part of their natural protection from cardiovascular disease.

Back to Top | Article Outline
Triglycerides, insulin, leptin, and fat mass

Baseline levels of serum triglycerides and insulin were similar between sexes as in a normal population, whereas serum leptin concentrations were trend-wise (> 30%) higher in female than in male patients. Although the magnitude of this sex difference was not significant, it was comparable to the degree of sex differences in leptin levels in a healthy population.

Antiretroviral therapy increased serum triglycerides, insulin and leptin levels predominantly in our female, and to a lesser extent in our male HIV patients (Fig. 2, Table 2). Even though we were not surprised to find rising leptin levels during HAART [30,31], we had not necessarily expected sharper increases in the female patients as compared with the male HIV-infected patients. Of note, the twofold increase in serum leptin levels in women (Fig. 2) is rather pronounced in view of animal studies, showing that induction of inflammation by lethal doses of endotoxin increased leptin levels only 2.5-fold [32].

Interestingly, HIV-infected men and women gained fat mass to comparable extents, but the increase in leptin and insulin levels was clearly more pronounced in the female patients (Fig. 2). Yet, we found a moderate correlation between the increase in leptin levels and the gain in fat mass in our female patients, but not in male patients. The moderate degree of correlation, however, indicates that the preferential increase in leptin levels in women was not solely dependent on the increase in fat mass. This is in line with previous findings indicating that circulating leptin levels do not correlate directly with weight changes in HIV-infected patients or reflect exclusively adipose tissue mass [33–35].

In view of several previous reports, peripheral insulin resistance could be an explanation for the elevations in serum insulin in these patients [36]. Higher insulin concentrations may then have contributed to the increase in serum leptin levels, independently of body fat mass [37–39]. Finally, lower energy expenditure after successful antiretroviral treatment [15] may have been associated with an increase in leptin concentrations in this HIV-infected population [40].

It is of interest that elevated insulin [41] and triglyceride levels [42] may represent additional markers for the risk of coronary heart disease, especially in women. In addition, leptin seems to play a role in atherogenesis via different mechanisms. Leptin promotes platelet aggregation [43], induces plasminogen activator inhibitor-1 synthesis [44], up-regulates pro-inflammatory cytokines [45], and generates oxidative stress [46]. Hence, it is conceivable that the elevation of leptin levels in the female HIV patients during HAART is pathophysiologically relevant and enhances the development and propagation of vascular disease [47]. Increased insulin and triglyceride levels further support the contention that female patients are at a higher risk to develop pro-atherogenic side-effects during HAART than are male patients.

Back to Top | Article Outline
Adhesion molecules

Endothelial cell damage is present early in HIV infection, but the understanding of markers and mechanisms remains incomplete [48]. It has been reported that HIV may infect vascular EC directly [49], and induce shedding of adhesion molecules from the cell surface, possibly due to oxidative stress [50]. In addition, HIV and various opportunistic pathogens may exert indirect deleterious effects on EC, conceivably via pro-inflammatory cytokines.

Serum cE-selectin is a specific endothelial activation marker, which can indicate HIV-associated vascular inflammation [51], and/or atherosclerosis and the consecutive development of cardiovascular disease [18,52,53].

In this study, HIV-infected patients had higher baseline levels of cE-selectin than healthy controls confirming a previous cross-sectional study [48]. HIV-infected male patients had almost 50% higher baseline levels of cE-selectin than female patients (Fig. 1) as would be expected from healthy controls [54,55]. The preserved sex differences in baseline cE-selectin levels in HIV infection may indicate that female sex protects against endothelial activation in HIV-infected individuals.

However, during HAART, serum cE-selectin levels declined in the male, but not in the female patients (Fig. 2), despite similar reductions in viral load. As a consequence, sex differences in cE-selectin were no longer apparent 6 months after initiation of HAART (P > 0.05, Fig. 2). This may be interpreted as evidence that HAART suppressed immunological/inflammatory processes in EC less effectively in female patients than in male patients.

A limitation of this study is that the question of whether the observed metabolic disturbances were related specifically to the use of PI could not be addressed in this setting. Indeed, previous studies on the association of metabolic changes with certain components of combinational regimens have produced inconsistent data. Whereas disturbances in lipid metabolism have been reported during HIV-therapy without PI [56], ‘switch studies’ have indicated that cholesterol and triglyceride levels fall when PI-containing therapy is discontinued [57]. Furthermore, PI have been shown to increase concentrations of serum triglycerides and atherogenic lipoproteins even in healthy volunteers [58]. Only very recently, in vitro experiments have shown a direct and dose-dependent influence of PI on insulin-stimulated glucose uptake in adipocytes [59].

As it cannot be ruled out completely that the stage of disease also influenced metabolic changes to a certain extent, only HIV and AIDS patients who were in very good clinical condition were enrolled in the study.

However, to answer more comprehensively the question of whether there is a cause and effect relationship between the use of PI-containing HAART and metabolic disturbances would require a comparison of (at least) two groups of patients, one receiving a PI-based regimen and the other receiving a non-NRTI in combination with two NRTI.

In summary, adverse metabolic effects of a HAART regimen were more pronounced in women than in men in this study. Female patients exhibited more distinct increases in serum levels of LDL, LDL : HDL, triglycerides, insulin and leptin decreased more in men than in women. Hence, female HIV-infected patients seem to loose part of their natural protection from atherosclerosis during antiretroviral therapy.

Further studies are necessary to determine whether these pro-atherogenic effects are related specifically to PI and whether in women non-NRTI-based regimens are as effective as PI-based regimens immunologically and virologically and with fewer adverse metabolic effects.

Back to Top | Article Outline

References

1. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. Natl Vital Stat Rep 1999, 47: 1 –45.

2. Hammer SM, Squires KE, Hughes MD. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337: 725 –733.

3. Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 1999, 13 (suppl 1): S49 –S59.

4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093 –2099.

5. Yanovski A, Miller KD, Kino T. et al. Endocrine and metabolic evaluation of human immunodeficiency virus- infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999, 84: 1925 –1931.

6. Berthold HK, Parhofer KG, Ritter MM. et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999, 246: 567 –575.

7. Behrens G, Dejam A, Schmidt H. et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13: F63 –F70.

8. Walli R, Herfort O, Michl GM. et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12: F167 –F73.

9. Bush TL, Barrett-Connor E, Cowan LD. et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75: 1102 –1109.

10. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prevent Med 1991, 20: 47 –63.

11. Ickovics JR, Rodin J. Women and AIDS in the United States: epidemiology, natural history, and mediating mechanisms. Health Psychol 1992, 11: 1 –16.

12. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000, 85: 35 –41.

13. Periard D, Telenti A, Sudre P. et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100: 700 –705.

14. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84: 1932 –1937.

15. Pernerstorfer-Schoen H, Schindler K, Parschalk B. et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 1999, 13: 2389 –2396.

16. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.MMWR 1992, 41:1–19.

17. Constans J, Pellegrin JL, Peuchant E. et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994, 24: 416 –420.

18. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997, 132: 151 –156.

19. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999, 27: 77 –81.

20. Lukaski HC, Johnson PE. A simple, inexpensive method of determining total body water using a tracer dose of D2O and infrared absorption of biological fluids. Am J Clin Nutr 1985, 41: 363 –370.

21. Shizgal HM. Validation of the measurement of body composition from whole body bioelectric impedance. Infusionstherapie 1990, 17 (suppl 3): 67 –74.

22. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996, 64: S489 –S497.

23. Kautzky-Willer A, Fasching P, Jilma B, Waldhausl W, Wagner OF. Persistent elevation and metabolic dependence of circulating E-selectin after delivery in women with gestational diabetes mellitus. J Clin Endocrinol Metab 1997, 82: 4117 –4121.

24. Jilma B, Dallinger S, Hergovich N, Eichler HG, Richter V, Wagner OF. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules [see comments]. J Clin Endocrinol Metab 2000, 85: 1748 –1751.

25. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989, 52: 48 –60.

26. Constans J, Marchand JM, Conri C. et al. Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study. Ann Med 1995, 27: 683 –685.

27. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 2000, 11: 41 –46.

28. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet 1998, 351: 1958. 1958.

29. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62: 707 –714.

30. Paganelli R, Mezzaroma I, Mazzone AM, Pinter E, Aiuti F. Leptin levels in HIV-positive patients treated with HAART [letter]. AIDS 1999, 13: 2479. 2479.

31. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999, 13: 2251 –2260.

32. Grunfeld C, Zhao C, Fuller J. et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996, 97: 2152 –2157.

33. Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly WG, Santiago JV, Landt M. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metab 1997, 46: 303 –305.

34. Ballinger A, Kelly P, Hallyburton E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin Sci (Colch) 1998, 94: 479 –483.

35. Grunfeld C, Pang M, Shigenaga JK. et al. Serum leptin levels in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996, 81: 4342 –4346.

36. Mulligan K, Grunfeld C, Tai VW. et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23: 35 –43.

37. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996, 45: 988 –991.

38. Haffner SM, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL, Laakso M. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 1997, 21: 393 –399.

39. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996, 81: 4406 –4413.

40. Grinspoon S, Corcoran C, Miller K. et al. Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr 1998, 68: 720 –725.

41. Giltay EJ, Lambert J, Gooren LJ, Elbers JM, Steyn M, Stehouwer CD. Sex steroids, insulin, and arterial stiffness in women and men. Hypertension 1999, 34: 590 –597.

42. D'Agostino RB, Russell MW, Huse DM. et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000, 139: 272 –281.

43. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999, 48: 426 –429.

44. De Mitrio V, De Pergola G, Vettor R. et al. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism 1999, 48: 960 –964.

45. Loffreda S, Yang SQ, Lin HZ. et al. Leptin regulates proinflammatory immune responses. FASEB J 1998, 12: 57 –65.

46. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13: 1231 –1238.

47. Leyva F, Godsland IF, Ghatei M. et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998, 18: 928 –933.

48. Seigneur M, Constans J, Blann A. et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997, 77: 646 –649.

49. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986, 83: 7089 –7093.

50. Constans J, Seigneur M, Blann AD. et al. Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction. Thromb Haemost 1998, 80: 1015 –1017.

51. Mandell BF, Calabrese LH. Infections and systemic vasculitis. Curr Opin Rheumatol 1998, 10: 51 –57.

52. Hwang SJ, Ballantyne CM, Sharrett AR. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96: 4219 –4225.

53. Blann AD, Farrell A, Picton A, McCollum CN. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb Res 2000, 97: 209 –216.

54. Jilma B, Eichler HG, Breiteneder H. et al. Effects of 17 beta-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab 1994, 79: 1619 –1624.

55. Blann AD, Daly RJ, Amiral J. The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Br J Haematol 1996, 92: 498 –500.

56. Saint-Marc T, Partisani M, Poizot-Martin I. et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13: 1659 –1667.

57. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13: 805 –810.

58. Purnell JQ, Zambon A, Knopp RH. et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14: 51 –57.

59. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275: 20251 –20254.

Cited By:

This article has been cited 42 time(s).

Journal of the International AIDS Society
Caring for women living with HIV: gaps in the evidence
Loutfy, MR; Sherr, L; Sonnenberg-Schwan, U; Walmsley, SL; Johnson, M; Monforte, AD
Journal of the International AIDS Society, 16(): -.
ARTN 18509
CrossRef
Hiv Clinical Trials
Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens
Tashima, KT; Bausserman, L; Alt, EN; Aznar, E; Flanigan, TP
Hiv Clinical Trials, 4(1): 29-36.

Salud Publica De Mexico
Hyperlipidemia and glucose intolerance in patients with HIV infection receiving antiretroviral therapy
Castro-Sansores, CJ; Santos-Rivero, A; Lara-Perera, D; Gonzalez-Martinez, P; Alonso-Salomon, G; Gongora-Biachi, RA
Salud Publica De Mexico, 48(3): 193-199.

American Journal of Cardiology
Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia
Kannel, WB; Giordano, M
American Journal of Cardiology, 94(7): 901-906.
10.1016/j.amjcard.2004.06.025
CrossRef
Plos One
Beneficial Effects of HIV Peptidase Inhibitors on Fonsecaea pedrosoi: Promising Compounds to Arrest Key Fungal Biological Processes and Virulence
Palmeira, VF; Kneipp, LF; Rozental, S; Alviano, CS; Santos, ALS
Plos One, 3(): -.
ARTN e3382
CrossRef
Journal of Antimicrobial Chemotherapy
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors
von Hentig, N; Babacan, E; Lennemann, T; Knecht, G; Carlebach, A; Harder, S; Staszewski, S; Haberl, A
Journal of Antimicrobial Chemotherapy, 62(3): 579-582.
10.1093/jac/dkn204
CrossRef
Hiv Clinical Trials
Evaluation of sex differences of Fosamprenavir (with and without ritonavir) in HIV-infected men and women
Hoffman, RM; Umeh, CC; Garris, C; Givens, N; Currier, JS
Hiv Clinical Trials, 8(6): 371-380.
10.1310/hct0806-371
CrossRef
Hiv Infection and the Cardiovascular System
Pathogenesis of the HAART-associated metabolic syndrome
Behrens, GMN; Stoll, M; Schmidt, RE
Hiv Infection and the Cardiovascular System, 40(): 83-96.

Antiviral Therapy
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy
Martinez, E; Tuset, M; Milinkovic, A; Miro, JM; Gatell, JM
Antiviral Therapy, 9(5): 649-663.

Atherosclerosis
Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART)
Leitner, JM; Pernerstorfer-Schoen, H; Weiss, A; Schindler, K; Rieger, A; Jilma, B
Atherosclerosis, 187(1): 177-185.
10.1016/j.atherosclerosis.2005.09.001
CrossRef
Metabolic Syndrome and Related Disorders
Human Immunodeficiency Virus and Highly Active Antiretroviral Therapy-Associated Metabolic Disorders and Risk Factors for Cardiovascular Disease
Anuurad, E; Semrad, A; Berglund, L
Metabolic Syndrome and Related Disorders, 7(5): 401-409.
10.1089/met.2008.0096
CrossRef
AIDS
Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease
Behrens, GMN; Meyer-Olson, D; Stoll, M; Schmidt, RE
AIDS, 17(): S149-S154.

European Journal of Clinical Investigation
Longitudinal evolution of HIV-1-associated lipodystrophy is correlated to serum cortisol: DHEA ratio and IFN-alpha
Christeff, N; de Truchis, P; Melchior, JC; Perronne, C; Gougeon, ML
European Journal of Clinical Investigation, 32(): 775-784.

Journal of Womens Health
Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women
Massad, LS; Evans, CT; Minkoff, H; Watts, DH; Greenblatt, RM; Levine, AM; Anastos, K; Young, M; Seifer, DB; Golub, E; Cohen, M
Journal of Womens Health, 15(5): 591-598.

Journal of Clinical Laboratory Analysis
Human immunodeficiency virus genotype and hypertriglyceridemia
Anderson, SJ; Bradley, JF; Ferreira-Gonzalez, A; Garrett, CT
Journal of Clinical Laboratory Analysis, 16(4): 202-208.
10.1002/jcla.10042
CrossRef
American Journal of Cardiology
Lipoprotein abnormalities related to women's health
Bittner, V
American Journal of Cardiology, 90(): 77I-84I.
PII S0002-9149(02)02637-1
CrossRef
Jaids-Journal of Acquired Immune Deficiency Syndromes
Metabolic abnormalities in HIV disease and injection drug use
Dobs, A; Brown, T
Jaids-Journal of Acquired Immune Deficiency Syndromes, 31(): S70-S77.
10.1097/01.QAI.0000028067.79472.C2
CrossRef
Journal of Medical Virology
Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons
Boulassel, MR; Morales, R; Murphy, T; Lalonde, RG; Klein, MB
Journal of Medical Virology, 78(9): 1158-1163.
10.1002/jmv.20676
CrossRef
Expert Opinion on Drug Metabolism & Toxicology
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy
Umeh, OC; Currier, JS
Expert Opinion on Drug Metabolism & Toxicology, 2(2): 273-283.
10.1517/17425255.2.2.273
CrossRef
Arquivos Brasileiros De Endocrinologia E Metabologia
Vitamin D deficiency in HIV-infected individuals: one more risk factor for bone loss and cardiovascular disease?
Conrado, T; Miranda, DD; Bandeira, F
Arquivos Brasileiros De Endocrinologia E Metabologia, 54(2): 118-122.

International Journal of Epidemiology
Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy
Heath, KV; Chan, KJ; Singer, J; O'Shaughnessy, MV; Montaner, JSG; Hogg, RS
International Journal of Epidemiology, 31(5): 1016-1020.

AIDS
Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe
La Rovere; Pellegatta; Sticca; Bezzi; Basetti, D; Rosso, R; Ferrando, S; Cristina; Lipreri; Merlo; Bianchi; Schneider; Brambilla, P; Guarino; Giaquinto, C; Giacomet, V; Ebo; Romano; Maccabruni, A; Consolini; Castelli, G; Cursi; Palma; Anzidei; Chiodi; Gabiano, C; Garetto; Mazza; Rabusin; Bohlin, AB; Mur, A; Botet, FA; de Jose, I; Ciria, L; Grosch-Worner, I; Marczynska, M; Nadal, D; Zucol, F; Wyler, CA; Egli, D; Kind, C; Rudin, C; Cheseaux, JJ; Duppenthaler, A; Aebi, C
AIDS, 18(): 1443-1451.
10.1097/01.aids.0000131334.38172.01
CrossRef
Drug Safety
Sex differences in antiretroviral therapy-associated intolerance and adverse events
Clark, R
Drug Safety, 28(): 1075-1083.

Lancet Infectious Diseases
HIV-associated dyslipidaemia: pathogenesis and treatment
Oh, J; Hegele, RA
Lancet Infectious Diseases, 7(): 787-796.

Clinical Infectious Diseases
Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin
Nagy, GS; Tsiodras, S; Martin, LD; Avihingsanon, A; Gavrila, A; Hsu, WC; Karchmer, AW; Mantzoros, CS
Clinical Infectious Diseases, 36(6): 795-802.

Hiv Medicine
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)
Gazzard, B
Hiv Medicine, 6(): 1-61.

Hiv Medicine
The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations
Shafran, SD; Mashinter, LD; Roberts, SE
Hiv Medicine, 6(6): 421-425.

Clinical Infectious Diseases
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities
Anderson, PL; Kakuda, TN; Lichtenstein, KA
Clinical Infectious Diseases, 38(5): 743-753.

AIDS Research and Human Retroviruses
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
Aberg, JA; Zackin, RA; Brobst, SW; Evans, SR; Alston, BL; Henry, WK; Glesby, MJ; Torriani, FJ; Yang, YJ; Owens, SI; Fichtenbaum, CJ
AIDS Research and Human Retroviruses, 21(9): 757-767.

Pharmacological Research
Gender differences in the treatment of HIV infection
Floridia, M; Giuliano, M; Palmisano, L; Vella, S
Pharmacological Research, 58(): 173-182.
10.1016/j.phrs.2008.07.007
CrossRef
Plos One
HIV Aspartyl Peptidase Inhibitors Interfere with Cellular Proliferation, Ultrastructure and Macrophage Infection of Leishmania amazonensis
Santos, LO; Marinho, FA; Altoe, EF; Vitorio, BS; Alves, CR; Britto, C; Motta, MCM; Branquinha, MH; Santos, ALS; d'Avila-Levy, CM
Plos One, 4(3): -.
ARTN e4918
CrossRef
New England Journal of Medicine
Class of antiretroviral drugs and the risk of myocardial infarction
Friis-Moller, N; Reiss, P; Sabin, CA; Weber, R; Monforte, AD; El-Sadr, W; De Wit, S; Kirk, O; Fontas, E; Law, MG; Phillips, A; Lundgren, JD
New England Journal of Medicine, 356(): 1723-1735.

Journal of Clinical Endocrinology & Metabolism
Regulation of adiponectin in human immunodeficiency virus-infected patients: Relationship to body composition and metabolic indices
Tong, Q; Sankale, JL; Hadigan, CM; Tan, G; Rosenberg, ES; Kanki, PJ; Grinspoon, SK; Hotamisligil, GS
Journal of Clinical Endocrinology & Metabolism, 88(4): 1559-1564.
10.1210/jc.2002-021600
CrossRef
AIDS
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in anti retroviral-naive subjects: 48-week results
Murphy, RL; Sanne, I; Cahn, P; Phanuphak, P; Percival, L; Kelleher, T; Giordano, M
AIDS, 17(): 2603-2614.
10.1097/01.aids.0000096930.51231.5d
CrossRef
Antiviral Therapy
Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy
Umpleby, AM; Das, S; Stolinski, M; Shojaee-Moradie, F; Jackson, NC; Jefferson, W; Crabtree, N; Nightingale, P; Shahmanesh, M
Antiviral Therapy, 10(5): 663-670.

European Journal of Clinical Investigation
Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects
Schindler, K; Haider, D; Wolzt, M; Rieger, A; Gmeinhart, B; Luger, A; Nowotny, P; Ludvik, B
European Journal of Clinical Investigation, 36(9): 640-646.

Gender Medicine
Antiretroviral pharmacokinetic profile: A review of sex differences
Ofotokun, I; Chuck, SK; Hitti, JE
Gender Medicine, 4(2): 106-119.

AIDS
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials
d'Arminio Monforte, A; González, L; Haberl, A; Sherr, L; Ssanyu-Sseruma, W; Walmsley, SL; on behalf of Women for Positive Action,
AIDS, 24(8): 1091-1094.
10.1097/QAD.0b013e3283390db3
PDF (138) | CrossRef
AIDS
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial
Haas, DW; Zala, C; Schrader, S; Piliero, P; Jaeger, H; Nunes, D; Thiry, A; Schnittman, S; Sension, M; for the Protocol AI424-009 Study Group,
AIDS, 17(9): 1339-1349.

PDF (138)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens
Anastos, K; Lu, D; Shi, Q; Tien, PC; Kaplan, RC; Hessol, NA; Cole, S; Vigen, C; Cohen, M; Young, M; Justman, J
JAIDS Journal of Acquired Immune Deficiency Syndromes, 45(1): 34-42.
10.1097/QAI.0b013e318042d5fe
PDF (449) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Antiretroviral Therapy in HIV-Positive Women Is Associated With Increased Apolipoproteins and Total Cholesterol
Rimland, D; Guest, JL; Hernández-Ramos, I; del Rio, C; Le, N; Brown, W
JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(3): 307-313.
10.1097/01.qai.0000220164.72113.12
PDF (101) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Letters to the Editor: Short-Term Lipid Changes Associated With Highly Active Antiretroviral Therapy in Naive HIV-Infected Patients
Palacios, R; Santos, J; Ruiz, J; González, M; Valdivielso, P; Márquez, M; González-Santos, P
JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(2): 250-251.

PDF (2538)
Back to Top | Article Outline
Keywords:

HAART; protease inhibitors; sex differences; dyslipidaemia; soluble E-selectin

© 2001 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.